PMC5173493_01
(a) Abdominal CT performed 2 months before TLV administration showed cirrhosis with massive ascites. (b) A comparison of the abdominal CT performed 2 months before TLV administration with that performed 1 month after TLV administration revealed an increase in ascites. (c) A comparison of abdominal CT performed 1 month after TLV administration with that performed 2 months after TLV administration showed no significant increase or decrease in ascites. (d) Abdominal CT performed 6 months after TLV administration showed a significant decrease in ascites.
1349-7235-55-3273-g001.jpg
PMC5173493_01_1349-7235-55-3273-g001.jpg
g001
No signs of any recurrence of HCC were observed (Fig. 1a). A comparison of the abdominal CT performed 2 months before tolvaptan administration with that performed 1 month after tolvaptan administration showed an increase in ascites (Fig. 1b), and the patient had clearly gained weight from 37.6 kg immediately before tolvaptan administration to 52.2 kg. A comparison of the CT performed 1 month after tolvaptan administration with that performed 2 months after tolvaptan administration revealed no significant increase or decrease in ascites (Fig. 1c). The abdominal CT performed at 6 months revealed the ascites to have markedly decreased (Fig. 1d).
Clinical course after admission; Despite the administration of tolvaptan at 3.75 mg on the 1st hospital day, no increase in urine volume or decrease in body weight was noted. Therefore, the dose of tolvaptan was increased to 7.5 mg on the 7th hospital day, but there was still no increase in urine volume or decrease in body weight.
1349-7235-55-3273-g002.jpg
PMC5173493_01_1349-7235-55-3273-g002.jpg
g002
The course after admission is presented in Fig. 2.